Factors associated with false-positive and false-negative fecal immunochemical test results for colorectal cancer screening

Gastrointestinal Endoscopy

Volumn 81, Issue 3, 2015, Pages 596-607

  Wong, Martin C S ^a,b   Ching, Jessica Y L ^a   Chan, Victor C W ^a   Lam, Thomas Y T ^a   Luk, Arthur K C ^a   Ng, Simon S M ^a   Sung, Joseph J Y ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DYSPLASIA; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FECAL IMMUNOCHEMICAL TEST; FEMALE; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SMOKING; ADENOMA; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; EVALUATION STUDY; LABORATORY DIAGNOSIS; MIDDLE AGED; OCCULT BLOOD; PROCEDURES; RETROSPECTIVE STUDY;

ADENOMA; ADULT; AGED; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OCCULT BLOOD; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84923494077     PISSN: 00165107     EISSN: 10976779     Source Type: Journal    
DOI: 10.1016/j.gie.2014.08.006     Document Type: Article

References (46)

1. GLOBOCAN 2012. Cancer Fact Sheet. Colorectal Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available at: http://globocan.iarc.fr/factsheet.asp. Accessed May 8, 2014.
2. Sung JJ, Lau JY, Goh KL, et al Asia Pacific Working Group on Colorectal Cancer. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 2005;6:871-6.
3. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.
4. Jorgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002;50:29-32.
5. Mandel JS, Church TR, Ederer F, et al. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999;91:434-7.
6. Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008;103:1541-9.
7. Sung J.J, Ng S.C, Chan F.K, et al. An Updated Asia Pacific Consensus Recommendations on Colorectal Cancer Screening. Gut. Epub 2014 Mar 19. doi:10.1136/gutjnl-2013-306503.
8. Pignone M, Rich M, Teutsch SM, et al. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:132-41.
9. Levin B, Lieberman AD, McFarland B, et al American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the U.S. Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008;58:130-60.
10. Advisory Committee on Cancer Prevention. Recommendations on cancer screening in the European Union. Eur J Cancer 2000;36:1473-8.
11. Levi Z, Rozen P,Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007;146:244-55.
12. Park D, Ryu S, Kim Y, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average-risk undergoing colorectal cancer screening. Am J Gastroenterol 2010;105:2017-25.
13. Morikawa T, Kato J, Yamaji Y, et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005;129:422-8.
14. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007;99:1462-70.
15. Denters MJ, Deutkom M, Bossuyt PM, et al. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer. Gastroenterology 2012;142:497-504.
16. Lee JK, Liles EG, Bent S, et al. Accuracy of fecal immunochemical tests for colorectal cancer. Ann Intern Med 2014;160:171-81.
17. Stegeman I, de Wijkerslooth TR, Stoop EM, et al. Risk factors for false positive and for false negative results in screening with fecal occult blood testing. Int J Cancer 2013;133:2408-14.
18. Chiang T-H, Lee Y-C, Tu C-H, et al. Performance of the immunochemical fecal occult blood test in predicting lesions in the lower gastrointestinal tract. CMAJ 2011;183:1474-81.
19. Keyzer-Dekker CMG, van Esch L, de Vries J, et al. An abnormal screening mammogram causes more anxiety than a palpable lump in benign breast disease. Breast Cancer Res Treat 2012;134:253-8.
20. Mccann J, Stockton D, Godward S. Impact of false-positive mammorgraphy on subsequent screening attendance and risk of cancer. Breast Cancer Res 2002;4:R11.
21. Lane JM, Chow E, Young G, et al. Interval fecal immunochemical testing in a colonoscopic surveillance program speeds detection of colorectal neoplasia. Gastroenterology 2010;139:1918-26.
22. Chiu HM, Lee YC, Tu CH, et al. Association between early stage colon neoplasms and false-negative results from the fecal immunochemical test. Clin Gastroenterol Hepatol 2013;11:832-8.
23. Haug U, Knudsen AB, Brenner H, et al. Is fecal occult blood testing more sensitive for left- versus right-sided colorectal neoplasia? A systematic literature review. Expert Rev Mol Diagn 2011;11:605-16.
24. Haug U, Kuntz KM, Knudsen AB. Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia. Br J Cancer 2011;104:1779-85.
25. Wong MC, John GK, Hirai HW, et al. Changes in the choice of colorectal cancer screening tests in primary care settings from 7,845 prospectively collected surveys. Cancer Causes Control 2012;23:1541-8.
26. Wong MC, Hirai HW, Luk AK, et al. The knowledge of colorectal cancer symptoms and risk factors among 10,078 screening participants: are high risk individuals more knowledgeable? PLoS One 2013;8:e60366.
27. Wong MC, Ching JY, Hirai HH, et al. Perceived obstacles of colorectal cancer screening and their associated factors among 10,078 Chinese participants. PLoS One 2013;8:e70209.
28. Wong MC, Lam TYT, Tsoi KKF, et al. A validated tool to predict colorectal neoplasia and inform screening choice for asymptomatic subjects. Gut 2014;63:1130-6.
29. Ng SC, Ching JYL, Chan VCW, et al. Diagnostic accuracy of fecal immunochemical test for screening individuals with a family history of colorectal cancer. Aliment Pharmacol Ther 2013;38:835-41.
30. Wong MC, Ching JY, Lam TY, et al. Prospective cohort study of compliance with faecal immunochemical tests for colorectal cancer screening in Hong Kong. Prev Med 2013;57:227-31.
31. Wong MC, Tsoi KK, Ng SSM, et al. A Comparison of the acceptance of Immunochemical faecal occult blood test and colonoscopy in colorectal cancer screening: a prospective study among Chinese. Aliment Pharmacol Ther 2010;32:74-82.
32. Wong MC, Lam TY, Tsoi KK, et al. Predictors of colorectal advanced neoplasia for colorectal cancer screening. Am J Prev Med 2014;46:433-9.
33. Rex DK, Petrini JL, Baron TH, et al. Quality indicators for colonoscopy. Gastrointest Endosc 2006;63:S16-28.
34. Imperiale TF, Wagner DR, Lin CY, et al. Results of screening colonoscopy among persons 40 to 49 years of age. N Engl J Med 2002;346:1781-5.
35. Lieberman DA, Prindiville S, Weiss DG, et al; VA Cooperative Study Group 380. Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. JAMA 2003;290:2959-67.
36. Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer 2006;42:216-27.
37. Anderson JC, Alpern Z, Sethi G, et al. Prevalence and risk of colorectal neoplasia in consumers of alcohol in a screening population. Am J Gastroenterol 2005;100:2049-55.
38. Betés M, Muñoz-Navas MA, Duque JM, et al. Use of colonoscopy as a primary screening test for colorectal cancer in average risk people. Am J Gastroenterol 2003;98:2648-54.
39. Colditz GA, Atwood KA, Emmons K, et al. Harvard report on cancer prevention volume 4: Harvard Cancer Risk Index. Risk Index Working Group, Harvard Center for Cancer Prevention. Cancer Causes Control 2000;11:477-88.
40. Vogelaar I, van Ballegooijen M, Schrag D, et al. How much can current interventions reduce colorectal cancer mortality in the U.S.? Cancer 2006;107:1624-33.
41. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005;294:914-23.
42. Chan AT, Giovannucci EL, Schernhammer ES, et al. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med 2004;140:157-66.
43. Morikawa T, Kato J, Yamaji Y, et al. Sensitivity of immunochemical fecal occult blood test to small colorectal adenomas. Am J Gastroenterol 2007;102:2259-64.
44. Brenner H, Tao S, Haug U. Low-dose aspirin use and performance of immunochemical fecal occult blood tests. JAMA 2010;304:2513-20.
45. Bujanda L, Lanas Á, Quintero E, et al COLONPREV Study Investigators. Effect of aspirin and antiplatelet drugs on the outcome of the fecal immunochemical test. Mayo Clin Proc 2013;88:683-9.
46. Haug T, Hundt S, Brenner H. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Am J Gastroenterol 2010;105:682-90.